drugset / Trial / NCT01872065

Safety and Tolerability Study of ARC-520 in Healthy Volunteers

NCT01872065

Phase 1 Completed 54 enrolled Arrowhead Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of ARC-520 in normal, adult volunteers.

Timeline

Start
2013-07
Primary completion
2014-09
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ARC-520 Unknown Intravenous

Indications

No indication recorded.